2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Abstract Number: 1999

NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Abstract Number: 447

Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage
Abstract Number: 728

Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases
Abstract Number: 305

Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Abstract Number: 2049

National Estimates of Pain Medication Use in Patients with Osteoarthritis
Abstract Number: 2316

National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014
Abstract Number: 2181

Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study
Abstract Number: 2805

Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls
Abstract Number: 1177

Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Abstract Number: 1850

Needs Assessment of Rheumatology Fellowship Program Directors on the Need for a Health Disparities Curriculum for Our Fellowship Programs
Abstract Number: 92

Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls
Abstract Number: 713

NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity
Abstract Number: 1989

Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal
Abstract Number: 382

Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis
Abstract Number: 1457

Neurological Involvement in a Cohort of Primary Sjogren’s Syndrome Patients: Results of a Multicenter Italian Study
Abstract Number: 2143

Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center
Abstract Number: 706

Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments
Abstract Number: 379

Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group
Abstract Number: 930

Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
Abstract Number: 1226

Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Abstract Number: 2789

Neutrophil Extracellular Traps Induce Tissue-Invasive Macrophages in Granulomatosis with Polyangiitis Dominated by Ear, Nose and Throat Manifestations
Abstract Number: 685

Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus
Abstract Number: 2804

Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration
Abstract Number: 1023

Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals
Abstract Number: 1469

New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Abstract Number: 1274

New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Abstract Number: 1185

New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission
Abstract Number: 1813

New Medications Are Needed for Children with Juvenile Idiopathic Arthritis
Abstract Number: 970

New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Abstract Number: 653

Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
Abstract Number: 1020

NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus
Abstract Number: 2046

NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis
Abstract Number: 1870

NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis
Abstract Number: 1331

No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab
Abstract Number: 1330

No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years
Abstract Number: 2120

No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Abstract Number: 184

No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA
Abstract Number: 2867

Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Abstract Number: 1116

Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data
Abstract Number: 2502

Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Abstract Number: 2758

Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis
Abstract Number: 480

Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database
Abstract Number: 1370

Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
Abstract Number: 377

Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Abstract Number: 1164

Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis
Abstract Number: 28

Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction
Abstract Number: 1253

Novel Nonsense Variant and Entire Deletion of TNFAIP3 Cause Haploinsufficiency of A20 Clinically Distinct from Behçet’s Disease
Abstract Number: 1188

Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls
Abstract Number: 2011

Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)
Abstract Number: 104

Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Abstract Number: L03

NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].